One of the most convincing evidence is that several modified NAFLD mice, including SREBP-1c transgenic mice, ob/ob, and db/db mice, can induce insulin resistance.[15,16] Therefore, modulation of IR is a potential strategy for NAFLD treatment. This evidence concerns the gene SREBF1 and metabolic dysfunction-associated steatotic liver disease.